Background {#Sec1}
==========

About 70% of preterm neonates at \<28 weeks of gestational age are widely affected by patent ductus arteriosus (PDA) \[[@CR1]\], and about one-third of very low birth weight (VLBW) neonates are symptomatic \[[@CR2]\]. PDA is a cardiac condition that might be associated with infant mortality \[[@CR3],[@CR4]\] and morbidity such as bronchopulmonary dysplasia (BPD) \[[@CR5],[@CR6]\], intraventricular hemorrhage (IVH) \[[@CR7]\], and necrotizing enterocolitis (NEC) \[[@CR8],[@CR9]\]. No causality has been established between PDA and these morbidities \[[@CR10],[@CR11]\] nor any evidence favoring specific treatment that is likely to decrease the associated mortality or severe morbidities; however, closure of PDA has been successful \[[@CR12]\]. Although numerous PDA therapies were universally accepted, in due course, they were proven ineffective, harmful, and periodically catastrophic \[[@CR13]\]. As a result, PDA management has been constrained by complex uncertainties in diagnosis, allocation of clinical priority, treatment identification, and preferred management modality \[[@CR14]\] that have led to gaps between evidence and routine practice. Furthermore, different practices exist within and between countries \[[@CR15]-[@CR17]\]. For instance, in Japan, wide variations are reported in indomethacin use, enteral feeding adjustment, fluid management, and ventilation strategies, although diagnosis criteria between institutions do not vary \[[@CR18]\]. These inconsistencies have resulted in confusion and uncertainty in the medical community and raise questions about treatment ethics. Under these uncertainties, standard PDA treatment should follow 'risks versus benefits' rationale quantified by robust evidence tailored to the conditions of individual neonates \[[@CR10],[@CR11]\].

Translating research into daily practice and changing physicians' behavior could be a daunting challenge for various reasons, e.g., the massive amount of generated evidence \[[@CR19]\] and different levels of healthcare system delivery (e.g. professional and patient-level) might inhibit practice change \[[@CR19]\]. In such predicaments, clinical guidelines might be useful to uphold treatment effectiveness and to discourage ineffective treatment exercises \[[@CR20]\]. Among various educational strategies to endorse professional practice and execution of research findings, targeted planning e.g., outreach visits by experts, interactive workshops, and multifaceted program have shown consistent usefulness, whereas the evidence was inconsistent for the effectiveness of other strategies such as passive dissemination of educational materials, involvement of opinion leaders, audit and feedback, and instructive educational sessions \[[@CR19],[@CR21]\]. Also, the effectiveness of the approaches may vary by types of target professional performances, societal or cultural factors, and differences in healthcare systems \[[@CR21],[@CR22]\]. In neonatology, evidence on effective educational methods is lacking except for that on neonatal resuscitation \[[@CR23],[@CR24]\]. An absence of effective methods to implement guidelines therefore could either hinder the improvement of treatment quality or lead to hazardous clinical outcomes, especially in a sensitive population such as neonates.

Therefore, in this study, we hypothesized that workshops on PDA management guidelines by guideline developers will have a positive effect on physicians' change in practice and will thereby reduce the associated adverse outcomes in preterm neonates, including mortality. We held face-to-face workshops at two tertiary-level neonatal intensive care units (NICUs) in Japan, which were used as intervention sites, and sought to evaluate their impact on physicians' routine practices and clinical outcomes in premature neonates with PDA before and after the workshops.

Methods {#Sec2}
=======

Study design, setting, and participants {#Sec3}
---------------------------------------

This was a controlled before-and-after study conducted in tertiary-level NICUs in Japan. The study included 15 physicians from two intervention NICUs---Kurashiki Central Hospital (KCH) and Osaka Medical Center and Research Institute for Maternal and Child Health (OMCRI-MCH)---and all VLBW neonates weighing ≤1500 g admitted to the Neonatal Research Network of Japan (NRNJ) from April 2008 to March 2010. The two intervention NICUs were selected by convenience and by the study investigators. The included intervention sites were eligible as they were the central NICUs providing tertiary-level care in individual region. The NICUs offer a range of crucial healthcare services such as obstetrics and cardiac or general pediatric surgeries. At the point of this study, the NICUs managed extremely preterm neonates (22--25 weeks of gestational age), including neonates with surgical requirement. The other NICUs (*N* = 88) under the NRNJ network served as controls in this study.

Intervention {#Sec4}
------------

We held 1-day workshops on the clinical practice guideline for PDA management in preterm neonates \[[@CR25],[@CR26]\] in February 2009 to assess the workshop impact on practice change at KCH and OMCRI-MCH. The guideline used in the workshop was developed according to the international standards for assessing the quality of practice guidelines (AGREE) \[[@CR27]\] and published originally in Japanese \[[@CR25],[@CR26]\]. All the recommendations made in the Japanese guideline version were translated in English and available as an Additional file [1](#MOESM1){ref-type="media"}. Two neonatologists from the guideline development group organized and led the workshops, which consisted of a 2-hour lecture on the guidelines, a question-and-answer session, and case reviews (Figure [1](#Fig1){ref-type="fig"}). The first half of the lecture focused on the guideline development process, including question selection, formulating recommendations from evidence mapping, and consensus building through the refined Delphi process \[[@CR28]\]. The remainder of the lecture presented the final recommendations of the guidelines and their rationale. In the case reviews, the lecturers and participants discussed several PDA cases (their clinical courses and problems related to PDA). The case selection was particularly driven by the usual difficulty surrounding PDA management (e.g., poor response to the treatment and delayed case detection) and related adverse outcomes (respiratory deterioration, bowel problems, renal failure, etc.).Figure 1Flow diagram of the study. Legend: WS: workshop.

It has been suggested that physicians' practice change could be hindered by various factors embedded deeply in individual contexts; therefore, it is likely that the change will vary from one setting to another \[[@CR19]\]. Furthermore, evidence effectiveness on multifaceted educational interventions, educational outreach visits, interactive workshops, and several others are found consistent \[[@CR21]\]. We therefore designed a multifaceted intervention consisting of educational material (guidelines), educational outreach visits by content experts, face-to-face interactions (question-and-answer sessions \[Q&A\] and case reviews), and local consensus developing process (case reviews). The national guideline and content experts helped overcome the potential barriers possibly aroused from a lack of motivation, leadership, knowledge, and skills to adopt the current evidence and clinical practice change \[[@CR19]\]. The content experts were selected mainly based on their proficient expertise in evidence-based medicine and PDA management and experiences in organizing similar educational training in Japan; however, they did not receive any targeted training for this study. Case reviews helped to develop a consensus for the implication of the guidelines into the local context.

Participating physicians did not receive any information about their outcome evaluation at baseline i.e., management skill measures from confidence rating (CR) and the Sheffield Peer Review Assessment Tool (SPRAT) and neonates' clinical outcomes. There were no interventions in the control NICUs.

Outcome measures {#Sec5}
----------------

### Pre- and post-assessment of physicians' PDA management skills in the intervention NICUs {#Sec6}

We assessed the impact of the workshops on physicians' practice change 1 month before and after using a structured questionnaire on PDA management in the intervention NICUs (KCH and OMCRI-MCH) only. We evaluated confidence levels using CR scores \[[@CR29]\] and clinical skill assessment using SPRAT \[[@CR30]\]. CR is a validated method to assess trainee physicians' self-reported confidence in a scale ranges from 1 to 4: not confident (CR 1), satisfactory but lack confidence (CR 2), confident in some cases (CR 3), and fully confident in most of the cases (CR 4) \[[@CR29]\]. The workshop physicians self-rated the CR for PDA diagnosis, prophylaxis, and treatment management (Additional file [2](#MOESM2){ref-type="media"}). SPRAT was used to peer review the participants and consists of 24 questions covering good clinical care, good medical practice, teaching and training, physician-patient relationships, and working relationships with colleagues, plus an overall measurement \[[@CR30]\]. Using a 6-grade performance scale, in which 1 is the lowest and 6 is the highest, reviewers assigned the trainees as appropriate. The questions in SPRAT have been described previously \[[@CR30]\]. One senior neonatologist from each of the intervention sites (was not a workshop participant) rated the participants' performance based on how well they complied with the guideline recommendations for PDA management (Additional file [1](#MOESM1){ref-type="media"}). The evaluation time of the physicians' practicing skill was selected arbitrary based on our assumption that the change would require at least a month to detect an intervention effect. We hypothesized that without any educational training, physicians' confidence and skill in daily practice would not change *in a month*. Assessments for CR and SPRAT were not approached in the control NICUs.

### Neonatal data and endpoints in the intervention and control NICUs {#Sec7}

We reviewed data on VLBW neonates weighing ≤1500 g admitted at the intervention NICUs from 1 April 2008 to 31 March 2010 and compared these data with the VLBW neonates at the control NICUs of NRNJ. The NRNJ is a large multicenter network, of which most tertiary-level NICUs are members. We excluded neonates with known congenital anomalies or moribund infants (no resuscitative care administration was decided at birth). Data abstractors collected data on VLBW neonates admitted to all NICUs using a standard network database operation manual. Primary outcomes were physicians' PDA management skills and neonatal mortality at discharge. Secondary outcomes included significant PDA or PDA based on echocardiography; indomethacin use to treat PDA; PDA ligation; respiratory distress syndrome (RDS); BPD defined as oxygen use at 36 weeks corrected gestational age with oxygen use on 28th day after birth; severe IVH of grade 3 or 4 \[[@CR31]\]; periventricular leukomalacia (PVL); stage 2 NEC or higher based on Bell's criteria \[[@CR32]\]; retinopathy of prematurity (ROP) of grade 3 (middle, late) or above, as per Japanese ROP grading guidelines; late onset sepsis; air leak syndrome; and persistent pulmonary hypertension of the newborn (PPHN).

Statistical analyses {#Sec8}
--------------------

The sample sizes (number of physicians and neonates) were derived based upon practicality and feasibility of available resources at the time this study was conducted. As this was a pilot study, no existing relevant study from Japan was available to justify our sample size calculation.

To assess the impact of the workshop, we compared physicians' skills (average CR and SPRAT scores in each of their assessed domains) between pre- and post-workshop period using Wilcoxon signed-rank test. The maternal and neonatal characteristics were compared between the pre- and post-workshop years (April 2008 to March 2009 and April 2009 to March 2010, respectively) using Chi-square tests, Fisher's exact tests, and *t*-tests. Multivariable logistic regression analyses compared neonatal outcomes between pre- and post-workshop periods, adjusting for potential confounders i.e., gender, gestational age, Apgar score at 5 minutes, C-section, antenatal steroid use, maternal hypertension, chorioamnionitis, outborn, and the interaction term between the periods (pre- vs. post-workshop) and sites (intervention vs. control NICUs). A significant interaction term between the periods and sites indicates a significant difference in the intervention impact between the intervention and control NICUs. The ORs with 95% confidence interval (CI) determination in the regression model were separately reported for both the intervention and control sites. We also conducted difference-in-differences (DID) analysis for the binary outcomes accounting for aggregate time effect \[[@CR33],[@CR34]\]. We addressed missing data using complete case analyses and excluded observations with missing predictor variables. The data management and statistical analyses were performed using PASW statistics 18.0 (SPSS Inc., Hong Kong) and SAS 9.3 (SAS Institute, Inc., Cary, NC). A significant level of 2-sided *p* value \<0.05 was used.

Ethical approval {#Sec9}
----------------

This study was approved by the ethical committees of the Kurashiki Central Hospital and Osaka Medical Center and Research Institute for Maternal and Child Health. Written informed consent for data collection and usage were obtained from all physicians included in the study. Data collection from the NRNJ database was approved by the internal review board at the Tokyo Women's Medical University. Written informed consent for data collection and usage at the NRNJ were obtained from the parents or guardians of all included neonates.

Results {#Sec10}
=======

Physicians' PDA management skills {#Sec11}
---------------------------------

Fifteen physicians participated in the workshops and questionnaire (100% response rate; no missing data). Following the workshops, this study found a significant increase in overall CR (pre- vs. post-workshop: 2.14 vs. 2.47, *p* = 0.02) and a borderline increase in overall SPRAT score (4.14 vs. 4.50, *p* = 0.05) (Table [1](#Tab1){ref-type="table"}). Some domain scores in SPRAT e.g., good clinical care and teaching and training had marked post-workshop increases (*p* = 0.03 and 0.04).Table 1**Pre- and post-workshop comparisons of physicians' PDA management skillsConfidence ratingPre-WS mean (SD)Post-WS mean (SD)*p*** **value**Prophylactic indomethacin2.13 (0.99)2.53 (1.13)0.14Treatment of symptomatic PDA2.20 (0.86)2.60 (0.99)0.06Decision of PDA ligation1.87 (0.83)2.40 (0.99)0.02Monitoring during indomethacin administration (e.g., signs and complications)2.60 (0.91)2.73 (0.80)0.41Other PDA treatments (e.g., transfusion, diuretics)2.00 (0.76)2.33 (0.82)0.03PDA treatments in chronic phase1.87 (0.99)2.20 (0.77)0.21Fluid management during PDA treatments2.20 (0.94)2.47 (0.83)0.16Respiratory management during PDA treatments2.13 (0.74)2.47 (0.83)0.06Nutrition during PDA treatments2.27 (0.88)2.47 (0.99)0.32Overall2.14 (0.76)2.47 (0.80)0.02Sheffield Peer Review Assessment ToolGood clinical care4.11 (0.56)4.49 (0.76)0.03Maintain good medical practice3.95 (0.52)4.36 (0.77)0.03Teaching and training4.10 (0.99)4.43 (0.92)0.04Relationship with patients4.67 (0.77)4.89 (0.97)0.08Working relationships with colleagues4.13 (0.36)4.43 (0.73)0.09Overall4.14 (0.42)4.50 (0.71)0.05Wilcoxon signed-rank test was used, and *p* value \<0.05 was considered statistically significant. There were no missing data. Pre-WS: before the workshops; Post-WS: after the workshops; 95% CI: confidence interval; confidence rating score range: 1 to 4; Sheffield Peer Review Assessment Tool score range: 1 to 6

Maternal and neonatal characteristics {#Sec12}
-------------------------------------

The analyses of neonates' data included 294 (pre-workshop: 146; post-workshop: 148) and 6,234 (pre-workshop: 3,322; post-workshop: 2,912) neonates in the two intervention NICUs and the other 88 control NICUs, respectively. We observed a significant post-workshop difference in chorioamnionitis and antenatal steroids use in both the intervention and control NICUs as well as a significant increase in maternal hypertension, premature rupture of the membrane, and C-section in the control NICUs (Table [2](#Tab2){ref-type="table"}).Table 2**Pre- and post-workshop comparisons of maternal and neonatal characteristicsIntervention NICUs (** ***N*** **= 2)Control NICUs (** ***N*** **= 88)**VariablesPre-WS (*n* = 146)Post-WS (*n* = 148)*p* valueMD or OR (95% CI)Pre-WS (*n* = 3,322)Post-WS (*n* = 2,912)*p* valueMD or OR (95% CI)Maternal age (years)31.2 ± 5.131.6 ± 5.40.560.43 (−0.78, 1.64)31.2 ± 5.231.4 ± 5.30.370.12 (−0.15, 0.39)Missing1016647Primipara121 (82.9)116 (78.4)0.320.75 (0.42, 1.34)2,836 (85.4)2,514 (86.3)0.271.08 (0.94, 1.25)Multiple pregnancy42 (28.8)40 (27.0)0.730.92 (0.55,1.53)834 (25.1)681 (23.4)0.110.91 (0.81, 1.02)Maternal hypertension22 (15.1)25 (16.9)0.671.15 (0.61, 2.14)625/3,320 (18.8)589/2,815 (20.9)0.041.14 (1.01, 1.29)Maternal diabetes3 (2.1)3 (2.0)0.980.99 (0.20, 4.97)44/3,320 (1.3)52/2,749 (1.9)0.081.44 (0.96, 2.15)PROM51 (34.9)47 (31.8)0.560.87 (0.53, 1.41)896/3,322 (26.9)866/2,888 (30.0)\<0.011.16 (1.04, 1.29)Chorioamnionitis19/146 (13.0)46/146 (31.5)\<0.013.08 (1.70, 5.58)494/3,271 (15.1)467/2,652 (17.6)\<0.011.20 (1.05, 1.38)Antenatal steroids use80/146 (54.8)97/147 (66.0)0.051.6 (0.998, 2.57)1,446/3,320 (43.6)1,474/2,827 (52.1)\<0.011.41 (1.28, 1.56)Gestational age (weeks)28.2 ± 3.628.4 ± 3.20.670.19 (−0.58, 0.98)28.4 ± 3.228.3 ± 3.20.82−0.02 (−0.14, 0.18)Birth weight (grams)1,001.2 ± 323.9991.7 ± 322.30.8−9.53 (−83.6, 64.5)1,027.2 ± 303.61,032.7 ± 301.70.475.53 (−9.53, 20.59)Birth length (cm)34.8 ± 4.134.4 ± 4.50.45−0.38 (−1.39, 0.62)35.3 ± 4.035.3 ± 4.20.850.02 (−0.19, 0.23)Missing41232158Head circumference (cm)25.2 ± 2.725.4 ± 3.30.50.24 (−0.46, 0.95)25.6 ± 2.825.6 ± 2.90.9−0.01 (−0.16, 0.14)Missing81296188Gender (male)80 (54.8)72 (48.7)0.290.78 (0.49, 1.24)1,670/3,322 (50.3)1,505/2,911 (51.7)0.261.06 (0.96, 1.17)Outborn9 (6.2)5 (3.4)0.260.53 (0.17, 1.63)245 (7.4)225 (7.7)0.61.05 (0.87, 1.27)Vertex presentation95/146 (65.1)100/144 (69.4)0.421.22 (0.75, 1.99)2,258/3,309 (68.2)1,859/2,658 (70.0)0.151.08 (0.97, 1.21)Cesarean section110 (75.3)105 (70.9)0.390.80 (0.48, 1.34)2,502 (75.3)2,268 (77.9)0.021.15 (1.03, 1.30)Apgar score \< 7 at 5 min36/145 (24.8)36/148 (24.3)0.920.97 (0.57, 1.66)801/3,219 (24.9)682/2,863 (23.8)0.330.94 (0.84, 1.06)Chi-square, Fisher's exact test, or *t*-test was used as appropriate. *p* value \<0.05 was considered statistically significant. All the estimates were rounded. Binary outcome variables with missing data are indicated by the denominators showing the numbers of assessed infants. *MD* mean difference, *OR* odds ratio, *CI* confidence intervals. MD or OR estimates correspond as appropriate. Unless otherwise stated, values represent number of neonates with their percentages in the parentheses. *NICUs* neonatal intensive care units, *PROM* premature rupture of the membrane; Pre-WS: before the workshops; Post-WS: after the workshops.

Neonatal clinical outcomes {#Sec13}
--------------------------

The odds of neonates' discharge mortality improved significantly (from 15/146 to 5/148, relative risk reduction \[RRR\] −0.67; adjusted odds ratio \[AOR\] 0.30, 95% CI 0.1 to 0.89) during the post-workshop period, after adjusting for potential covariates (Table [3](#Tab3){ref-type="table"}). There was also a significant mortality decline at the control sites (from 207/3,322 to 147/2,912, RRR −0.19; AOR 0.75, 95% CI 0.59 to 0.95) during the same period, and it was greater in the intervention sites than in the controls (Figure [2](#Fig2){ref-type="fig"}), although no statistical significance was observed. (*p* = 0.075). Similarly, the difference in reduction of mortality rate (−5.71%, 95% CI −11.6 to 0.12) between intervention and control sites went in favor of the intervention sites, although no statistical significance was observed. Additionally, we observed slight increases in the odds of a few variables in the control sites only during the post-workshop year. No significant differences for PDA, indomethacin administration, and PDA ligation were detected in the intervention and control sites.Table 3**Pre- and post-workshop comparisons of neonatal clinical outcomesIntervention NICUs (** ***N*** **= 2)Control NICUs (** ***N*** **= 88)Intervention vs. control group difference**OutcomesPre-WS *n* = 146 (%)Post-WS *n* = 148 (%)Unadjusted OR (95% CI)Adjusted OR (95% CI)Pre-WS *n* = 3,322 (%)Post-WS *n* = 2,912 (%)Unadjusted OR (95% CI)Adjusted OR (95% CI)DID in post- vs. pre-WS (95% CI)\*\*Mortality15 (10.3)5 (3.4)0.31 (0.11, 0.86)\*0.30 (0.1, 0.89)\*207 (6.2)147 (5.1)0.80 (0.64, 0.99)\*0.75 (0.59, 0.95)\*−5.71 (−11.6, 0.12)RDS80 (54.8)90 (60.8)1.28 (0.81,2.04)1.55 (0.90, 2.68)1,893/3,322 (57.0)1,682/,2884 (58.3)1.06 (0.96, 1.17)1.05 (0.93, 1.18)4.68 (−6.86, 16.2)BPD25/141 (17.7)36/147 (24.5)1.51 (0.85, 2.67)1.66 (0.90, 3.07)490/3,282 (14.9)504/2,858 (17.6)1.22 (1.07,1.40)\*1.23 (1.06, 1.44)\*4.05 (−5.51, 13.6)Severe IVH6 (4.1)8 (5.4)1.33 (0.45, 3.94)1.38 (0.45, 4.27)145/3,322 (4.4)126/2,882 (4.4)1.00 (0.78, 1.28)1.0 (0.77, 1.30)1.29 (−3.68, 6.26)PVL3/146 (2.1)6/143 (4.2)2.09 (0.51, 8.51)2.09 (0.51, 8.51)112/3,318 (3.4)91/2,864 (3.2)0.94 (0.71, 1.24)1.0 (0.75, 1.34)2.34 (−1.77, 6.45)ROP14/139 (10.1)17/140 (12.1)1.23 (0.58, 2.61)1.50 (0.66, 3.41)289/2,429 (11.9)360/2,512 (14.3)1.23 (1.05, 1.46)\*1.33 (1.11, 1.60)\*0.36 (−7.97, 7.24)NEC3 (2.1)3 (2.0)0.98 (0.19, 4.97)1.11 (0.22, 5.72)55/3,322 (1.7)53/2,889 (1.8)1.11 (0.76, 1.62)1.01 (0.68, 1.51)−0.21 (−3.5, 3.09)Early sepsis3 (2.1)2 (1.4)0.65 (0.11, 3.97)0.65 (0.11, 3.97)88 (2.6)92 (3.2)1.20 (0.89, 1.61)1.27 (0.94,1.73)−1.21 (−4.29, 1.86)Late sepsis7 (4.8)6 (4.1)0.84 (0.27, 2.56)0.93 (0.30, 2.91)168/3,313 (5.1)172/2,880 (6.0)1.19 (0.95, 1.48)1.17 (0.93, 1.48)−1.64 (−6.48, 3.20)PDA47 (32.2)45 (30.4)0.92 (0.56, 1.51)0.97 (0.57, 1.65)1,286/3,322 (38.7)1,109/2,884 (38.5)0.99 (0.89, 1.10)0.95 (0.85, 1.07)−1.53 (−12.4, 9.35)Indomethacin43 (29.5)44 (29.7)1.01 (0.61, 1.67)1.01 (0.64, 1.86)1,229 (37.0)1,054 (36.2)0.97 (0.87, 1.07)0.93 (0.83, 1.05)1.08 (−9.63, 11.8)PDA ligation13 (8.9)7 (4.7)0.51 (0.20, 1.31)0.46 (0.17, 1.23)208/3,322 (6.3)185/2,865 (6.5)1.03 (0.84, 1.27)0.96 (0.77, 1.20)−4.37 (−10.3, 1.51)Air leak7 (4.8)4 (2.7)0.55 (0.16, 1.93)0.66 (0.17, 2.22)88/3,322 (2.7)93/2,880 (3.2)1.23 (0.91, 1.65)1.22 (0.90, 1.66)−2.67 (−7.09, 1.75)PPHN11 (7.5)15 (10.1)1.38 (0.61, 3.12)1.33 (0.57, 3.17)132/3,322 (4.0)152/2,872 (5.3)1.35 (1.06, 1.71)\*1.39 (1.09,1.79)\*1.28 (−5.28, 7.85)Variables with missing data are indicated by the denominators showing the numbers of the assessed neonates. Covariates included in the multiple logistic regression models were gender, gestational age, Apgar score \< 7 at 5 minutes, cesarean section, antenatal steroids use, maternal hypertension, chorioamnionitis, and outborn.Pre-WS: before the workshops; Post-WS: after the workshops. *OR* odds ratio, 95% *CI* 95% confidence interval, *RDS* respiratory distress syndrome, *BPD* bronchopulmonary dysplasia, *IVH* intraventricular hemorrhage, *PVL* periventricular leukomalacia, *ROP* retinopathy of prematurity, *NEC* necrotizing enterocolitis, *PDA* patent ductus arteriosus, *PPHN* persistent pulmonary hypertension.\*Statistically significant at the 5% probability level; \*\*DID: The difference in differences of neonatal outcomes (percentage points) = differences (%) between the post- and pre-WS for the intervention NICUs − differences (%) between the post- and pre-WS for the control NICUs, estimated using a probit model.Figure 2Mortality in intervention NICUs and control NICUs before and after the workshop. Legend: VLBW: very low birth weight, WS: workshop, NICUs: neonatal intensive care units.

Discussion {#Sec14}
==========

To our knowledge, this is the first study to examine the effects of professional-led guidelines implementation workshops on physicians' management skills of PDA and neonatal mortality and morbidities. We found that face-to-face outreach visits by guideline developers were effective in improving physicians' confidence and skills and may reduce mortality in preterm neonates.

Positive workshop impact in improving professionals' practices and health outcomes is supported by an earlier Cochrane review \[[@CR22]\]. Our findings add further support to the likelihood that changing physicians' behavior is achievable \[[@CR35]\], even in a highly controversial field like PDA \[[@CR10]-[@CR12],[@CR14],[@CR36]\]. Administered care could potentially be unnecessary or harmful, if the new evidence uptake is ineffectively practiced \[[@CR37],[@CR38]\]. This is especially important in Japan where preterm neonates are frequently monitored by functional echocardiography before receiving tailored care. Additionally, augmenting new evidence and a daily recommended uptake \[[@CR39]\] might be challenging for clinicians \[[@CR40]\]. Guideline translation could also be challenging due to its content and dissemination strategy \[[@CR19]\]. Therefore, it is crucial that these issues are effectively addressed in guideline implementation to influence physicians' routine practice \[[@CR21]\]. Although no single strategy has proven superior \[[@CR19],[@CR41]\], our study provides support to the effectiveness of a multifaceted educational intervention consisting of educational material (clinical guideline), expert outreach visits, and face-to-face interactive meetings including local consensus developing process (question-and-answer sessions and case reviews) to reduce the gap between research and practice \[[@CR21]\]. Additionally, the effects of any targeted interventions for behavior change are context-dependent \[[@CR21]\]. A unique work environment surrounding Japanese physicians such as extremely long work hours \[[@CR42]\] might make the workshop more effective because it is often difficult for them to have enough time to update their clinical knowledge and skill without well-organized educational sessions.

Similar to the intervention sites, mortality reduction in the control NICUs was also significant and was consistent with previous findings that reported an ongoing, marked improvement among VLBW neonates' mortality in Japan \[[@CR43],[@CR44]\]. Although the reduction was greater in the intervention sites compared to the controls, it was not statistically significant; therefore, we could not differentiate the positive workshop impact from the background declining trend of neonatal mortality. However, this should not diminish the importance of our findings because the guidelines were not intended to reduce PDA and its treatment rate but to reduce the risks of associated clinical deterioration and adverse outcomes by providing tailored care for a specific neonatal condition. Though insignificant, the PDA ligation rate in the intervention sites dropped during the post-workshop period, which may indicate an improvement in physicians' PDA management skills.

The strengths of our study include the use of a quasi-experimental design, a national registry database, and the employment of validated tools and standard guideline development methods \[[@CR30]\]. This comprehensive process might collectively influence physicians to comply with recommendations and encourage better practice adherence \[[@CR19],[@CR45]\]. Our study has illustrated the potential impact of the guidelines on neonatal clinical outcomes, for which evidence is scarce \[[@CR23],[@CR24]\]. Furthermore, our quasi-experimental design provides important complementary information when relevant trials are limited \[[@CR46]\]. Our study has several limitations. First, our sample size included a small number of workshop participants, warranting larger sample sizes in future studies. Second, physicians' assessment of CR was self-reported, which increases risk of recall bias. Although the SPRAT was validated in a previous study including general pediatricians at tertiary and secondary hospitals in the UK as a multisource peer review tool \[[@CR30]\], its reliability in this study setting (neonatologists and pediatricians in Japanese NICUs) as a single-source peer review was uncertain \[[@CR30]\]. Third, due to a lack of information, we could not investigate several management modalities, e.g., adoption of prophylactic with indomethacin and fluid and nutrition. Fourth, because of the study design, we could not exclude the possibility that improved mortality rates were caused by other factors. Fifth, although we conducted a 1-day workshop due to the practicality and feasibility of the available resources, more frequent workshops than a day-long workshop in this study could have a large effect \[[@CR47]\]. Finally, the external validity of this study is limited by the setting (tertiary hospitals in Japan); therefore, the findings must be interpreted with caution due to wide variations in PDA management between institutions and countries.

Conclusions {#Sec15}
===========

Face-to-face workshops by guideline developers can be a useful strategy to improve physicians' confidence and skills for PDA management and thereby might reduce PDA-associated mortality in preterm neonates especially in Japan. Our findings have added important knowledge to this area at a time when evidence on effective guideline implementation strategy in everyday practice is lacking, particularly in Japan. We propose an enhanced uptake of PDA management guidelines by increasing the number of professional-led workshops in Japan to stimulate guideline development and disseminate effective implementation strategies for better practice adherence. Future studies could provide further evidence by employing large multicenter cluster randomized controlled trials to evaluate the effectiveness of organization- and patient-oriented interventions \[[@CR41]\].
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